UCB SA (UCB.BR) Stock Fundamental Analysis
EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR
UCB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. UCB has only an average score on both its financial health and profitability. UCB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year UCB was profitable.
UCB had a positive operating cash flow in the past year.
Each year in the past 5 years UCB has been profitable.
Each year in the past 5 years UCB had a positive operating cash flow.
1.2 Ratios
UCB's Return On Assets of 6.14% is fine compared to the rest of the industry. UCB outperforms 64.00% of its industry peers.
The Return On Equity of UCB (10.62%) is better than 62.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.79%, UCB is in the better half of the industry, outperforming 62.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 14.89%.
The 3 year average ROIC (4.35%) for UCB is below the current ROIC(8.79%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROIC | 8.79% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
Looking at the Profit Margin, with a value of 17.31%, UCB is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
In the last couple of years the Profit Margin of UCB has remained more or less at the same level.
UCB's Operating Margin of 23.31% is fine compared to the rest of the industry. UCB outperforms 68.00% of its industry peers.
In the last couple of years the Operating Margin of UCB has declined.
UCB has a Gross Margin (71.52%) which is in line with its industry peers.
UCB's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UCB is still creating some value.
The number of shares outstanding for UCB remains at a similar level compared to 1 year ago.
UCB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for UCB has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.71 indicates that UCB is not in any danger for bankruptcy at the moment.
UCB has a better Altman-Z score (3.71) than 68.00% of its industry peers.
The Debt to FCF ratio of UCB is 3.29, which is a good value as it means it would take UCB, 3.29 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.29, UCB is doing good in the industry, outperforming 68.00% of the companies in the same industry.
UCB has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.30, UCB is doing good in the industry, outperforming 62.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 3.71 |
ROIC/WACC1.15
WACC7.63%
2.3 Liquidity
A Current Ratio of 1.36 indicates that UCB should not have too much problems paying its short term obligations.
UCB's Current ratio of 1.36 is in line compared to the rest of the industry. UCB outperforms 48.00% of its industry peers.
A Quick Ratio of 0.99 indicates that UCB may have some problems paying its short term obligations.
UCB has a Quick ratio of 0.99. This is comparable to the rest of the industry: UCB outperforms 56.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.57%, which is quite good.
UCB shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.86% yearly.
Looking at the last year, UCB shows a quite strong growth in Revenue. The Revenue has grown by 17.14% in the last year.
Measured over the past years, UCB shows a small growth in Revenue. The Revenue has been growing by 4.60% on average per year.
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
3.2 Future
The Earnings Per Share is expected to grow by 24.02% on average over the next years. This is a very strong growth
UCB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.27% yearly.
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y24.02%
Revenue Next Year16.61%
Revenue Next 2Y14.55%
Revenue Next 3Y13.59%
Revenue Next 5Y10.27%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.06, the valuation of UCB can be described as expensive.
UCB's Price/Earnings is on the same level as the industry average.
UCB is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.79, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 20.18, the valuation of UCB can be described as rather expensive.
UCB's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 21.38. UCB is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.06 | ||
| Fwd PE | 20.18 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as UCB.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of UCB is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.65 | ||
| EV/EBITDA | 14.44 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of UCB may justify a higher PE ratio.
A more expensive valuation may be justified as UCB's earnings are expected to grow with 34.53% in the coming years.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y37.44%
EPS Next 3Y34.53%
5. Dividend
5.1 Amount
UCB has a yearly dividend return of 0.66%, which is pretty low.
The stock price of UCB dropped by -20.39% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 3.11, UCB has a dividend in line with its industry peers.
With a Dividend Yield of 0.66, UCB pays less dividend than the S&P500 average, which is at 2.47.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.66% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years5
Div Non Decr Years5
5.3 Sustainability
UCB pays out 24.32% of its income as dividend. This is a sustainable payout ratio.
The dividend of UCB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.32%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EBR:UCB (4/25/2025, 7:00:00 PM)
149.7
+2.35 (+1.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.15%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap29.12B
Analysts75.2
Price Target211.54 (41.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.66% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP24.32%
Div Incr Years5
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.27%
PT rev (3m)8.64%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.49%
EPS NY rev (3m)9.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.06 | ||
| Fwd PE | 20.18 | ||
| P/S | 4.73 | ||
| P/FCF | 31.65 | ||
| P/OCF | 23.44 | ||
| P/B | 2.9 | ||
| P/tB | 60.04 | ||
| EV/EBITDA | 14.44 |
EPS(TTM)4.98
EY3.33%
EPS(NY)7.42
Fwd EY4.96%
FCF(TTM)4.73
FCFY3.16%
OCF(TTM)6.39
OCFY4.27%
SpS31.63
BVpS51.56
TBVpS2.49
PEG (NY)0.61
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROCE | 10.38% | ||
| ROIC | 8.79% | ||
| ROICexc | 10.16% | ||
| ROICexgc | 50.51% | ||
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% | ||
| FCFM | 14.95% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexcg growth 3Y-25.87%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.43 | ||
| Cap/Depr | 50.23% | ||
| Cap/Sales | 5.23% | ||
| Interest Coverage | 8.96 | ||
| Cash Conversion | 59.86% | ||
| Profit Quality | 86.39% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 3.71 |
F-Score9
WACC7.63%
ROIC/WACC1.15
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y24.02%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
Revenue Next Year16.61%
Revenue Next 2Y14.55%
Revenue Next 3Y13.59%
Revenue Next 5Y10.27%
EBIT growth 1Y178.99%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year142.79%
EBIT Next 3Y54.02%
EBIT Next 5Y31.2%
FCF growth 1Y106.74%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y63.21%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%